Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 14/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19780343 | 0.84 | KLKB1 (0.47) | KLKB1MAP4K1GSK3AMAPK10RIOK2 | |
| SCHEMBL19779818 | 0.84 | ALDH1A1 (0.43) | KLKB1MAP4K1 | |
| SCHEMBL18371612 | 0.83 | CA2 (0.46) | KLKB1MAP4K1MEN1KMT2AFAAH | |
| SCHEMBL19780636 | 0.82 | KLKB1 (0.47) | KLKB1MAP4K1 | |
| SCHEMBL19780021 | 0.80 | KLKB1 (0.46) | KLKB1MAP4K1FAAH | |
| SCHEMBL19780713 | 0.79 | KLKB1 (0.47) | KLKB1MAP4K1RAB9A | |
| SCHEMBL19779931 | 0.79 | KLKB1 (0.44) | KLKB1MAP4K1 | |
| SCHEMBL21190208 | 0.78 | ALDH1A1 (0.47) | KLKB1MAP4K1RAB9A | |
| SCHEMBL21179353 | 0.77 | KLKB1 (0.36) | KLKB1MAP4K1MEN1KMT2ARAB9A | |
| SCHEMBL19780026 | 0.77 | KLKB1 (0.48) | KLKB1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019142053-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-07-25 | — | — | WO | disclosed |